Sandoz’ global partnership with Gan & Lee covering three insulin biosimilar candidates has made progress after the Chinese firm reported positive Phase I data demonstrating pharmacokinetic and pharmacodynamic bioequivalence to the biosimilars’ reference brands.
Through a partnership signed in late 2018, Sandoz will market and supply Gan & Lee’s biosimilar Lantus (insulin glargine), Humalog...






